Research programme: RNA interference-based therapeutics - Phio Pharmaceuticals
Alternative Names: Anti-CTFG RNAi therapy; Anti-VEGF sd-rxRNA; rxRNA®; sd-rxRNA®; Self-delivering RNAi compounds - Phio PharmaceuticalsLatest Information Update: 28 Jan 2023
At a glance
- Originator RXi Pharmaceuticals Corporation
- Developer Phio Pharmaceuticals; RXi Pharmaceuticals; RXi Pharmaceuticals Corporation; University of Massachusetts Medical School
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Antivirals; Eye disorder therapies; Immunotherapies; Obesity therapies; Skin disorder therapies; Small interfering RNA
- Mechanism of Action Programmed cell death 1 receptor antagonists; Programmed cell death-1 ligand-1 inhibitors; RNA interference; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Eye disorders; Skin disorders
Highest Development Phases
- Preclinical COVID 2019 infections
- No development reported Cancer; CNS disorders; Eye disorders; Head and neck cancer; Inflammation; Malignant melanoma; Metabolic disorders; Obesity; Ovarian cancer; Respiratory tract disorders; Retinal disorders; Rheumatoid arthritis; Skin disorders
- Discontinued Cytomegalovirus retinitis
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Head-and-neck-cancer in USA (Parenteral)
- 28 Jan 2023 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (Parenteral)
- 28 Jan 2023 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Parenteral)